Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, caused primarily by smoking-related airflow obstruction and characterized by progressive dyspnea, chronic bronchitis, and exacerbations that drive hospitalizations and mortality. Despite approval of triple inhaled therapy (LABA/LAMA/ICS), exacerbation rates remain high in eosinophilic phenotypes, driving active trials in targeted biological therapies that have transformed severe asthma management.
Active trials investigate dupilumab for eosinophilic COPD (BOREAS and NOTUS trials showed reduced exacerbations), itepekimab (anti-IL-33), tezepelumab (anti-TSLP), mepolizumab for high-eosinophil COPD, phosphodiesterase-3/4 inhibitors, and novel mucolytic approaches. Disease-modifying trials targeting lung regeneration (all-trans retinoic acid, stem cell therapy) and alpha-1 antitrypsin augmentation for AATD-related COPD are also active.
COPD trials typically require post-bronchodilator FEV1/FVC <0.70 with documented history of exacerbations; blood eosinophil count ≥150 or ≥300 cells/μL is increasingly used to enrich biologic trials.
Frequently Asked Questions — pulmonary disease chronic obstructive copd Clinical Trials
How many clinical trials are currently recruiting for pulmonary disease chronic obstructive copd?
ClinicalMetric currently tracks 1 actively recruiting clinical trials for pulmonary disease chronic obstructive copd, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 1. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pulmonary disease chronic obstructive copd?
pulmonary disease chronic obstructive copd research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pulmonary disease chronic obstructive copd clinical trial?
Eligibility criteria for pulmonary disease chronic obstructive copd trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Danderyd Hospital 1 trial
Recruiting Clinical Trials
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional.
Full Disclaimer ·
Last Reviewed: April 2026 ·
Data Methodology